Singapore, Nov. 4 -- Novo Nordisk has announced the launch of Wegovy(R) in Hong Kong, now available at private clinics and selected pharmacies. Clinically proven for long-term weight management,Wegovy(R) represents a significant step forward in addressing the city's escalating health burden through evidence-based care for obesity as a chronic disease.

Wegovy(R) is the first once-weekly prescription weight-loss medication approved for adolescents aged 12 and above in Hong Kong.

Wegovy(R)contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that helps regulate appetite. By modulating brain's central hub for hunger and satiety control, Wegovy(R) helps patients lower their energy intake, enhances feelings of fullness and ...